Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond

Source: Targeting FGFR Signaling in Cancer: Bladder and Beyond
Listen to Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss their thoughts on what to know about managing toxicities associated with FGFR inhibitors in the treatment of urothelial cancer and other malignancies.
Alison Birtle, MD, FRCP, FRCR
person default
Ignacio Duran, MD, PhD
Released: May 4, 2021

In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment of urothelial cancer and other malignancies.   

Presenters:

Ignacio Durán, MD, PhD
Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain

Alison Birtle, MD, FRCP, FRCR
Honorary Senior Lecturer
Faculty of Health and Medicine
University of Manchester
Manchester, United Kingdom
Consultant Oncologist
Rosemere Cancer Centre
Lancashire Teaching Hospitals
Preston, Lancashire, United Kingdom

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Janssen Pharmaceutica NV

Related Content

Slides from Arjun Balar, MD on optimal selection of first-line treatment for patients with advanced urothelial cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD Released: May 6, 2021

Expert insight from Arjun Balar, MD, on choosing optimal first-line therapy for patients with advanced urothelial or bladder cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD person default Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 6, 2021 Expired: May 5, 2022

Expert insight from Arjun Balar, MD, on choosing optimal therapy for patients with advanced urothelial cancer after chemo and IO, from Clinical Care Options (CCO)

person default Arjun Balar, MD person default Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 4, 2021 Expired: May 3, 2022

Slides from Arjun Balar, MD on the role of antibody-drug conjugates in early stage urothelial cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD Released: May 4, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue